× Key messages Background Vitiligo Conclusions Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Conclusions

  • Unlike alopecia, vitiligo affects the epidermis, rather than deeper layers, and as such it lends itself to a topical rather than systemic treatment for many patients.
  • JAK inhibitors have potential to substantially re-pigment the face and body in vitiligo.
  • Ruxolitinib is currently recruiting for a Phase 3 study.